Global Tinea Corporis Drugs Market, By Drugs (Anti-Fungal, Others), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Tinea Corporis Drugs Market Analysis and Size
Mycotic diseases are global in distribution, but the majority of the cases are witnessed from tropical and subtropical countries. As the number of patients surges, the market also grows. Tinea corporis may be acute or chronic and have the possible tendency to spread to other infected sites. Several dermatologists diagnose tinea infections by examining the skin scraping under a microscope. The condition is mainly treated by topical antifungal agents and oral antifungal medicines, such as terbinafine and clotrimazoles.
Data Bridge Market Research analyses a growth rate in the tinea corporis drugs market in the forecast period 2023-2030. The expected CAGR of tinea corporis drugs market is tend to be around 3.50% in the mentioned forecast period. The market was valued at USD 16.6 billion in 2022, and it would grow upto USD 21.86 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Tinea Corporis Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Anti-Fungal, Others), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Amorphex Therapeutics Holdings, Inc (U.S.), Bausch Health Companies Inc. (Canada.), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Johnson & Johnson Services, Inc. (U.S.), LEO Pharma A/S (Denmark), Regeneron Pharmaceuticals Inc (U.S.), Astellas Pharma Inc. (Japan)
|
|
Market Opportunities
|
|
Market Definition
Tinea corporis is a fungal infection that develops on the skin's upper layer. It can occur or produce in any part of the body but majorly, it is developed on the legs and arms, predominantly in the glabrous skin. Tinea corporis commonly known as ringworm, appear like a ring structure on the skin. Fungal species that cause tinea corporis are Trichophyton rubrum, Microsporum canis and Epidermophyton floccosum.
Global Tinea Corporis Drugs Market Dynamics
Drivers
- Increasing Demand of Antifungals
The antifungal segment dominates the tinea corporis drugs market. This can be attributed to their highly-effective nature. Furthermore, they are the only feasible option as far as the treatment of fungal diseases is concerned. Additionally, a crucial reason for the dominance of the antifungal segment is the availability of several ways of using them. For instance, antifungal treatment is available in drugs, creams, shampoos, and others. Thus, all these factors boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is anticipated to speed up the market as most products are available in capsule, cream, gels or tablet form and it is a very convenient route of administration.
Opportunities
- Growing Schemes and R&D Activities
Established players are making their mark in several developing economies because of the liberal FDI policies regulated within the pharmaceuticals industry in such countries with rising consumer inclination towards maintaining aesthetic appearance. Furthermore, increasing R&D activities to develop particular antifungal products are also projected to create new growth opportunities for manufacturers operating in market.
- Increasing Demand for Retail Pharmacies
The rise in the number of tinea corporis medications delivered through various retail pharmacies and the growth in the number of retail pharmacies in highly developed countries can create opportunities for the market growth. Additionally, patients opt for retail pharmacies for purchasing drugs, as these are easily available.
Restraints/Challenges
- Limited Studies and Surveys
There are very few studies and surveys that is hampering the growth of the market. Only a small amount of data are available associated with the studies. A few studies mostly focused on groups from a single hospital wherein only a few number of patients are observed. Thus, this hampers the growth of the market.
- High Cost
The huge expenditure associated with tinea corporis medications hamper the market growth.
This tinea corporis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tinea corporis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Tinea Corporis Drugs Market Scope
The tinea corporis drugs market is segmented on the basis of drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Anti-Fungal
- Others
Route of Administration
- Oral
- Topical
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Tinea Corporis Drugs Market Regional Analysis/Insights
The tinea corporis drugs market is analyzed and market size insights and trends are provided by drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the tinea corporis drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for tinea corporis drugs market throughout the forecasted period due to increased high prevalence of skin diseases and increased healthcare expenditure.
Asia-Pacific dominates the market due to increased skin diseases by herbal medicine and synthetic medicines and easily available OTC drugs in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Tinea Corporis Drugs Market Share Analysis
The tinea corporis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to tinea corporis drugs market
Key players operating in the tinea corporis drugs market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
- Lupin (India)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Bausch Health Companies Inc. (Canada)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Johnson & Johnson Services, Inc. (U.S.)
- LEO Pharma A/S (Denmark)
- Regeneron Pharmaceuticals Inc (U.S.)
- Astellas Pharma Inc. (Japan)
SKU-